Association between hospital performance and after in-hospital cardiac arrest care

There is significant variation in survival rates after in-hospital cardiac arrest care. It is not clear whether better care is associated to better outcomes.

Hospital performance was assessed using six recommendations standardized for American hospitals participating in the program “Get with the Guidelines-Resuscitation”. 

The analysis included 149551 patients presenting in-hospital cardiac arrest in 447 centers between the years 2000 and 2012. The centers with best performance according to these guidelines also shown longer survival rates after resuscitation. Following cardiac arrest, for each 10% increase in hospital performance, chances of survival increased by 18%.  

Conclusion

Assistance quality based on the existing evidence on cardiopulmonary resuscitation varies largely throughout American hospitals and is associated to longer survival in patients presenting both shockable and non-shockable rhythms.

Monique L. Anderson
2014-11-17

Original title: Association between hospital performance and patient outcomes after in-hospital cardiac arrest care.

More articles by this author

Improved survival after out-of-hospital cardiac arrest with the use of automated external defibrillators

This study included patients presenting out of hospital cardiac arrest between 2006 and 2012 in The Netherlands to assess the impact of automated external...

Coronary flow reserve is associated to adverse events regardless angiographic severity.

This study included 329 consecutive patients derived to coronary angiography based on myocardial perfusion tests or PET scan (positron emission tomography). The extension and...

ITALIC PLUS: 6 months of double antiaggregation for no less than 24 months

Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6 and 24 months of double antiaggregation therapy...

DAPT TRIAL: double antiaggregation remains controversial

Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...